Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma

Cardiology in Review
Daniel C Cole, William H Frishman

Abstract

The use of proteasome inhibitors (PI) as targeted chemotherapeutics have significantly improved survival in patients with multiple myeloma (MM). However, rare and serious cardiovascular complications have occurred as a result of their use, most commonly congestive heart failure, hypertension, and arrhythmias. MM occurs in an aged population with many concurrent cardiovascular risk factors. The primary disease process also contributes to cardiovascular complications. Furthermore, many MM patients have prior exposure to cardiotoxic chemotherapy such as anthracyclines. Because of these occurrences, the identification, prevention, and management of cardiovascular complications is made increasingly difficult. Various clinical studies and case reports have documented cardiotoxicity among all 3 of the currently approved PIs, bortezomib, carfilzomib, and ixazomib. Carfilzomib has shown the highest rates of cardiotoxicity, whereas there is conflicting evidence regarding bortezomib's role in producing cardiotoxicity. However, various case reports have documented the existence of adverse cardiac effects. Higher frequencies of complications have also been seen in "real-life" populations with cardiovascular co-morbidities who were originall...Continue Reading

References

Mar 4, 2000·Circulation Research·S MiyataL A Leinwand
Mar 15, 2001·American Journal of Physiology. Heart and Circulatory Physiology·P J ReiserC Schomisch Moravec
Mar 2, 2002·The Journal of Biological Chemistry·Teru HideshimaKenneth C Anderson
May 23, 2006·Bone Marrow Transplantation·N J Bahlis, H M Lazarus
Jun 24, 2006·Circulation Research·Donna J ThueraufChristopher C Glembotski
Jul 10, 2007·Cancer Research·Susan D DemoMark K Bennett
Jul 25, 2007·Nature Reviews. Cancer·Teru HideshimaKenneth C Anderson
Jul 3, 2008·Journal of Agricultural and Food Chemistry·O Benavente-García, J Castillo
May 25, 2011·Journal of the National Cancer Institute·Amy M RuschakAaron D Schimmer
Jan 1, 2014·European Journal of Clinical Investigation·Hiroyuki Takase, Yasuaki Dohi
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Dec 15, 2015·Journal of Community Hospital Internal Medicine Perspectives·Marcelle G MeseehaMaximos N Attia
Jan 16, 2016·Blood Cancer Journal·A RosenthalA K Stewart
Nov 20, 2016·American Journal of Hematology·Hayan JouniJoerg Herrmann
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kenneth C Anderson
Feb 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert Z Orlowski, Sagar Lonial

❮ Previous
Next ❯

Citations

Jul 31, 2018·Future Oncology·Susanne Strifler, Stefan Knop
Aug 22, 2018·Expert Opinion on Drug Safety·Antonis A ManolisAntonis S Manolis
Nov 15, 2018·Expert Review of Proteomics·Thomas A Guerrero-GarciaPaul G Richardson
Mar 26, 2019·Expert Opinion on Investigational Drugs·Piotr Smolewski, Dominika Rydygier
Sep 7, 2019·Journal of Cell Science·Jisca MajoléePeter L Hordijk
Apr 26, 2019·Stem Cells Translational Medicine·Pooja NairIoannis Karakikes
Sep 5, 2020·Journal of Thrombosis and Thrombolysis·Wendy BottinorEiman Jahangir
Jun 29, 2018·Cardiovascular Toxicology·Brian B Hasinoff, Daywin Patel
Aug 7, 2019·Clinical Medicine Insights. Cardiology·Irving E PerezRhea Sancassani
Jul 22, 2020·Cardio-Oncology·Diego SadlerZeina Nahleh
Oct 13, 2018·European Cardiology·Athanasios KoutsoukisIoannis Paraskevaidis
Jan 22, 2021·Arteriosclerosis, Thrombosis, and Vascular Biology·Chi Keung Lam, Joseph C Wu
Nov 17, 2020·Frontiers in Cardiovascular Medicine·Namrita KaurWei Liu
Feb 4, 2021·Clinical Lymphoma, Myeloma & Leukemia·Claudia BellofioreConcetta Conticello
Mar 9, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Stefano FogliRomano Danesi
May 1, 2021·Journal of Clinical Medicine·Michał BohdanEwa Lewicka
Apr 19, 2021·Current Treatment Options in Oncology·Fei Fei GongNausheen Akhter
Sep 24, 2019·JACC. CardioOncology·Ronald M Witteles, Michaela Liedtke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.